The American Association of Clinical Endocrinologists (AACE) and its educational arm - the American College of Endocrinology (ACE) - in partnership with Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), announced a new public health initiative for people with type 2 diabetes mellitus called The Type 2 Talk:

Genzyme Corp. (NASDAQ: GENZ) reported that preliminary fourth-quarter revenue grew 23 percent to $1.15 billion from $938 million in the fourth quarter of 2009. For the year, revenue was $4.1 billion compared with $4.0 billion in 2009.

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results from a study of Vyvanse® (lisdexamfetamine dimesylate), assessing its effect in a model for Excessive Daytime Sleepiness (EDS).

Abbott (NYSE: ABT) has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years,

Genzyme Corp. (NASDAQ: GENZ) reported today that discussions between its financial advisors and financial advisors for Sanofi-Aventis are continuing and have expanded to include representatives of both companies.

AstraZeneca announced that the US Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for the investigational drug vandetanib.

Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.